Alpa Laboratorie

Who are in the management team of Alpa Laboratorie?

As of March 2022, the management team of Alpa Laboratorie includes Mahendra Singh Chawla (Chairman & Executive Director), Paresh Chawla (Managing Director), and several independent directors, along with a company secretary. The team features a mix of executive and independent roles.

As of March 2022, the management team of Alpa Laboratorie includes the following individuals:<BR><BR>1. Mahendra Singh Chawla - Chairman & Executive Director<BR>2. Pravin C Shah - Executive Director<BR>3. Paresh Chawla - Managing Director<BR>4. Sharad Chand Lunawat - Independent Director<BR>5. Devendra Baheti - Independent Director<BR>6. Krishna Das Malani - Independent Director<BR>7. Jyoti Jain - Independent Director<BR>8. Swati Bagh - Company Secretary & Compliance Officer<BR>9. Vitthal Kothana - Executive Director<BR>10. Sunil Valecha - Additional Director<BR>11. Saket Baheti - Independent Director<BR>12. Pratibha Lunawat - Independent Director<BR><BR>This team comprises a mix of executive, independent, and additional directors, along with a company secretary.

What does Alpa Laboratorie do?

Alpa Laboratories Ltd manufactures pharmaceutical formulations and operates in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 40 Cr and a net loss of 2 Cr, with a market cap of Rs 210 Cr.

Overview: <BR>Alpa Laboratories Ltd is a company engaged in the manufacture of pharmaceutical formulations, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>Alpa Laboratories was formed in 1967 and was incorporated as a Private Limited Company on March 18, 1988. It transitioned to a Public Limited Company on September 3, 1998. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 40 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 210 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 11.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.66 <BR>Return on Equity: 11.42% <BR>Price to Book: 1.21 <BR><BR>Contact Details: <BR>Address: 33/2 Pigdamber, A B Road Rau Indore Madhya Pradesh : 453446 <BR>Tel: 91-731-4294567 <BR>Email: is@alpalabs.com <BR>Website: http://www.alpalabs.in

Has Alpa Laboratorie declared dividend?

No Dividend History Available

Who are the peers of the Alpa Laboratorie?

Alpa Laboratorie's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, and Dr Reddy's Labs, among others. While Alpa Laboratorie's management risk and growth are average, it has a good capital structure and a 1-year return of 25%, lower than Divi's Lab's 51.69% but higher than Panch.Organics' -18.32%.

Peers: The peers of Alpa Laboratorie are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Panch.Organics, Syschem (India), Murae Organisor, Bafna Pharma, and Amwill.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Average management risk is found at Alpa Laboratorie and Panch.Organics, while below average management risk is noted at Syschem (India), Murae Organisor, Bafna Pharma, and the rest. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Murae Organisor, while below average growth is seen at Alpa Laboratorie, Panch.Organics, Torrent Pharma, and the rest. Excellent capital structure is present at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Alpa Laboratorie, Panch.Organics, while good capital structure is noted at Torrent Pharma and Bafna Pharma, and average capital structure is found at Syschem (India) and Murae Organisor.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Panch.Organics has the lowest at -18.32%. Alpa Laboratorie's 1-year return of 25.00% is higher than Panch.Organics but lower than Divi's Lab. Additionally, Panch.Organics and Syschem (India) have negative six-month returns.

What is the technical trend for Alpa Laboratorie?

As of June 5, 2025, Alpa Laboratorie's trend has shifted to bearish with moderate strength, driven by bearish MACD and moving averages, along with mixed signals from Bollinger Bands and KST.

As of 5 June 2025, the technical trend for Alpa Laboratorie has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and mildly bearish signals from Bollinger Bands and Dow Theory on both weekly and monthly time frames. The KST shows a mildly bullish trend on the weekly but remains mildly bearish monthly, indicating mixed signals. Overall, the bearish trend is reinforced by the recent price action and the performance relative to the Sensex.

Who are the top shareholders of the Alpa Laboratorie?

The top shareholders of Alpa Laboratorie include promoter Paresh Chawla with 34.26%, individual investors with 37.28%, and two foreign institutional investors holding 0.36%. There are no mutual funds or pledged promoter holdings in the company.

The top shareholders of Alpa Laboratorie are primarily its promoters, with Paresh Chawla being the individual with the highest holding at 34.26%. Additionally, individual investors collectively hold 37.28% of the shares. There are also two foreign institutional investors (FIIs) that hold a combined total of 0.36%. Notably, there are no mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

How big is Alpa Laboratorie?

As of 24th July, Alpa Laboratories Ltd has a market capitalization of 218.00 Cr, with net sales of 112.45 Cr and a net profit of 19.57 Cr over the latest four quarters. The company has shareholder's funds of 151.91 Cr and total assets of 182.37 Cr for the annual period ending March 2024.

As of 24th July, Alpa Laboratories Ltd has a market capitalization of 218.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Alpa Laboratories reported net sales of 112.45 Cr and a net profit of 19.57 Cr.<BR><BR>For the latest annual period ending March 2024, the company has shareholder's funds amounting to 151.91 Cr and total assets of 182.37 Cr.

How has been the historical performance of Alpa Laboratorie?

Alpa Laboratorie has shown steady growth in net sales and profit from Mar'20 to Mar'25, with net sales increasing from 85.97 Cr to 112.45 Cr, and profit before tax rising from 2.54 Cr to 25.67 Cr. Despite fluctuations in operating profit margins and rising raw material costs, the company's total assets and cash flow from operations have significantly improved.

Answer:<BR>The historical performance of Alpa Laboratorie shows a steady growth in net sales and profit over the years, with significant fluctuations in operating profit margins and expenses.<BR><BR>Breakdown:<BR>Alpa Laboratorie's net sales increased from 85.97 Cr in Mar'20 to 112.45 Cr in Mar'25, with a notable rise from 92.44 Cr in Mar'23 to 108.74 Cr in Mar'24. The total operating income followed a similar trend, reaching 112.45 Cr in Mar'25. However, raw material costs have also risen significantly, from 49.48 Cr in Mar'21 to 70.72 Cr in Mar'25, contributing to total expenditure growth from 82.62 Cr in Mar'20 to 107.70 Cr in Mar'25. Operating profit (PBDIT) saw fluctuations, peaking at 10.69 Cr in Mar'22 before dropping to 4.75 Cr in Mar'25. Profit before tax increased from 2.54 Cr in Mar'19 to 25.67 Cr in Mar'25, while profit after tax rose from 0.93 Cr in Mar'19 to 19.50 Cr in Mar'25, indicating improved profitability. The company's total assets grew from 120.43 Cr in Mar'20 to 222.63 Cr in Mar'25, with total liabilities also increasing from 120.43 Cr to 222.63 Cr in the same period. Cash flow from operating activities improved significantly to 18.00 Cr in Mar'25, compared to just 3.00 Cr in Mar'24, reflecting better operational efficiency. Overall, Alpa Laboratorie's financial performance demonstrates a positive growth trajectory despite rising costs and fluctuating profit margins.

Is Alpa Laboratorie overvalued or undervalued?

As of November 17, 2025, Alpa Laboratorie is considered overvalued and risky, with a PE Ratio of 9.02 and significant underperformance compared to peers like Sun Pharma and Cipla, as well as a year-to-date return of -33.37% against the Sensex's 8.72%.

As of 17 November 2025, the valuation grade for Alpa Laboratorie has moved from very attractive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 9.02, an EV to EBIT of -9.06, and an EV to EBITDA of -29.26, which suggest that the company's earnings and cash flows are under pressure.<BR><BR>In comparison to its peers, Alpa Laboratorie shows a stark contrast with Sun Pharma, which has a PE Ratio of 36.69 and an EV to EBITDA of 24.22, and Cipla, with a PE Ratio of 22.81 and an EV to EBITDA of 16.14. These comparisons highlight that Alpa Laboratorie is lagging behind its industry counterparts in terms of valuation metrics. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -33.37% compared to the Sensex's 8.72%, reinforcing the notion of its overvaluation.

Should I buy, sell or hold Alpa Laboratorie?

When is the next results date for Alpa Laboratories Ltd?

The next results date for Alpa Laboratories Ltd is 11 February 2026.

The next results date for Alpa Laboratories Ltd is scheduled for 11 February 2026.

Which are the latest news on Alpa Laboratorie?

Are Alpa Laboratories Ltd latest results good or bad?

Alpa Laboratories Ltd's latest results are largely negative, with a 78.65% decline in net profit to ₹1.90 crore despite an 11.09% increase in revenue to ₹29.05 crore. The stock fell over 6% post-announcement, indicating reduced investor confidence amid concerns about profitability and sustainability.

Alpa Laboratories Ltd's latest results present a mixed picture, but overall, they lean towards the negative side. In Q3 FY26, the company reported a net profit of ₹1.90 crore, which is a significant decline of 78.65% year-on-year. This sharp drop in net profit raises concerns about the company's profitability and operational stability.<BR><BR>On the positive side, revenue for the same quarter increased by 11.09% year-on-year, reaching ₹29.05 crore. This indicates some ability to grow sales, but the overall performance is overshadowed by the drastic fall in net profit. Additionally, the operating margin improved to 5.23% from a negative margin in the previous quarter, which is a positive sign, but still below historical levels.<BR><BR>The company's reliance on other income to support profitability is a critical concern, as it raises questions about the sustainability of its business model. The stock has reacted negatively to these results, declining over 6% in the trading session following the announcement, reflecting diminished investor confidence.<BR><BR>In summary, while there are some signs of revenue growth, the substantial decline in net profit and ongoing operational challenges suggest that the latest results are more bad than good for Alpa Laboratories Ltd.

Why is Alpa Laboratories Ltd falling/rising?

As of 11-Feb, Alpa Laboratories Ltd's stock price is Rs 70.15, down 6.22% today and 9.36% year-to-date, indicating a bearish trend despite increased investor participation. The stock has underperformed its sector and has seen consecutive declines over the past two days.

As of 11-Feb, Alpa Laboratories Ltd's stock price is falling, currently at Rs 70.15, which reflects a decrease of Rs 4.65 or 6.22%. The stock has underperformed its sector by 7.05% today and has been on a consecutive decline for the last two days, accumulating a total drop of 6.75% during this period. Over the past week, the stock has decreased by 0.50%, while it has seen a more significant decline of 7.21% over the past month. Year-to-date, the stock is down 9.36%, and over the past year, it has fallen by 33.82, contrasting sharply with the Sensex, which has gained 10.41% in the same timeframe.<BR><BR>Additionally, the stock's performance is indicated by its moving averages, which show that it is currently higher than the 20-day moving average but lower than the 5-day, 50-day, 100-day, and 200-day moving averages. This suggests a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 3.49% against the 5-day average, the overall sentiment remains negative, contributing to the stock's decline.